About

The HUREL micro liver technology platform of products and services was acquired by Visikol, Inc., in 2021. Visikol is a contract research services company that is focused on accelerating pharmaceutical and biotechnology development through providing clients with advanced cell culture and imaging services. The company also provides researchers with a suite of tissue imaging and cell culture products such as the HUREL micro liver portfolio.

---

How we started

The inspiration for Visikol began at Rutgers University in the fall of 2012 when Visikol Co-Founder Dr. Tom Villani first developed the Visikol tissue clearing reagents for use with a wide range of tissues. These reagents have been used by hundreds of research groups from all around the world from the jungles of Rwanda, researchers in the Arctic Circle, to researchers at major research institutions such as La Jolla Institute for Allergy and Immunology, Cedars-Sinai, Harvard, University of Pennsylvania, and the NIH. Today, Visikol has developed into a leading contract research services business that leverages its expertise in imaging, image analysis and advanced in vitro models to provide best-in-class services to its pharmaceutical and biotech clients.

---

Visikol leadership